News | Cardiac Imaging | September 13, 2017

Philips Showcases Integrated Vascular Solutions at VIVA 2017

Company will highlight patient-centric interventional peripheral vascular solutions for diagnosis, image-guided therapy and connected care

Philips Showcases Integrated Vascular Solutions at VIVA 2017

September 13, 2017 — Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from Sept. 11 – 14, 2017, applying advanced technologies and deep clinical insights to address peripheral vascular needs. With the addition of its recent acquisition, Spectranetics, Philips will for the first time highlight its expanded portfolio of interventional X-ray systems, advanced catheters for measurement and therapy, clinical informatics and services, including its Philips Azurion image-guided therapy platform, intravascular ultrasound (IVUS), Phoenix atherectomy system and Spectranetics' Stellarex drug-coated balloon.

More than 8 million people in the U.S. alone are affected by peripheral arterial disease (PAD) [1]. Many people do not experience symptoms and are not aware of even having the disease. In addition to having limited blood flow to the leg, patients are at increased risk for heart attack or stroke. Fortunately, PAD can be accessed and addressed through innovative solutions using minimally invasive procedures like atherectomy and cardiac imaging technology that may offer more accurate and reliable treatment options that can reduce recovery time for patients.

On Wednesday, Sept. 13, as part of the VIVA 17 Late-Breaking Clinical Trials program, Marianne Brodmann M.D., of the Medical University of Graz in Austria will present two-year data from the ILLUMENATE European randomized clinical trial (EU RCT) that evaluates how Spectranetics' Stellarex drug-coated balloon restores and maintains blood flow to arteries in patients with PAD. Stellarex received U.S. Food and Drug Administration (FDA) approval in July 2017. The ILLUMENATE EU RCT analyzes patency in the segment of diseased artery treated with Stellarex in over 300 patients from a challenging patient population.

The combination of Spectranetics' product range and Philips' portfolio of interventional imaging systems, devices, software and services offer innovative solutions for peripheral vascular therapy, according to the company. At this year's VIVA conference, Philips and Spectranetics will showcase technology including:

  • Stellarex, the only commercially available drug-coated balloon with two reported randomized controlled trials. It has demonstrated durability with consistently high patency rates in a wide range of patients, according to Philips;
  • Azurion is an image-guided therapy platform that enables clinicians to easily and confidently perform a range of routine and complex procedures, helping them to optimize interventional lab performance;
  • The Pioneer Plus catheter, a re-entry device with intravascular ultrasound (IVUS), a catheter-based imaging technology that allows physicians to visualize diseased vessels from inside the artery, to facilitate identification of true lumen location;
  • The Phoenix atherectomy system, which combines the benefits of existing atherectomy systems and delivers a hybrid [2] atherectomy option to help physicians tailor the treatment approach for each patient; and
  • SymphonySuite is Philips' comprehensive program that includes a robust set of tools to support efforts in opening, growing and maintaining office-based lab solutions.

For more information: www.usa.philips.com/healthcare

 

References

1. National Institutes of Health, Facts About Peripheral Arterial Disease (P.A.D.), NHLBI.NIH.gov, September 2017 
2. Directional cutting ability only available with Phoenix 2.4mm deflecting catheter

Related Content

Philips Launches Azurion With FlexArm
Technology | Angiography | January 17, 2019
Philips announced the launch of Azurion with FlexArm, designed to enhance positioning flexibility for image-guided...
SCCT Releases New Guideline for CT Use During TAVR
News | Computed Tomography (CT) | January 08, 2019
The Society of Cardiovascular Computed Tomography (SCCT) has released a new expert consensus document for computed...
Shimadzu Medical Systems USA Acquires Core Medical Imaging
News | Digital Radiography (DR) | January 08, 2019
Shimadzu Medical Systems USA has acquired Core Medical Imaging Inc. (CMI) in order to further expand its healthcare...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Hitachi Medical Systems Europe Introduces Third-Generation Intelligent Vector Flow Mapping
News | Cardiovascular Ultrasound | December 07, 2018
Hitachi Medical Systems Europe introduced what it calls the next level of intelligent Vector Flow Mapping (iVFM) at...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
AI Promising in Predicting Chronic Conditions From CT Scans
News | Artificial Intelligence | November 27, 2018
Zebra Medical Vision and Clalit Health Services announced the completion of two research projects that allow early...